Cyclacel Pharmaceuticals Inc (CYCC) - Total Assets
Based on the latest financial reports, Cyclacel Pharmaceuticals Inc (CYCC) holds total assets worth $4.40K USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cyclacel Pharmaceuticals Inc (CYCC) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cyclacel Pharmaceuticals Inc - Total Assets Trend (2000–2024)
This chart illustrates how Cyclacel Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check Cyclacel Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Cyclacel Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cyclacel Pharmaceuticals Inc's total assets of $4.40K consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.6% |
| Accounts Receivable | $237.00K | 5.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Cyclacel Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CYCC market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclacel Pharmaceuticals Inc's current assets represent 89.7% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 76.6% of total assets in 2024, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 5.8% of total assets.
Cyclacel Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Cyclacel Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
Cyclacel Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.77 | 1.07 | 15.15 |
| Quick Ratio | 5.77 | 1.07 | 14.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.62K | $521.00K | $24.22 Million |
Cyclacel Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Cyclacel Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.68 |
| Latest Market Cap to Assets Ratio | 3.48 |
| Asset Growth Rate (YoY) | -53.5% |
| Total Assets | $4.09 Million |
| Market Capitalization | $14.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cyclacel Pharmaceuticals Inc's assets at a significant premium (3.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cyclacel Pharmaceuticals Inc's assets decreased by 53.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cyclacel Pharmaceuticals Inc (2000–2024)
The table below shows the annual total assets of Cyclacel Pharmaceuticals Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.09 Million | -53.50% |
| 2023-12-31 | $8.80 Million | -68.61% |
| 2022-12-31 | $28.05 Million | -34.97% |
| 2021-12-31 | $43.14 Million | +17.21% |
| 2020-12-31 | $36.80 Million | +140.41% |
| 2019-12-31 | $15.31 Million | -22.78% |
| 2018-12-31 | $19.82 Million | -23.77% |
| 2017-12-31 | $26.00 Million | +32.25% |
| 2016-12-31 | $19.66 Million | -20.60% |
| 2015-12-31 | $24.76 Million | -15.73% |
| 2014-12-31 | $29.39 Million | -17.27% |
| 2013-12-31 | $35.52 Million | +83.53% |
| 2012-12-31 | $19.35 Million | -25.56% |
| 2011-12-31 | $26.00 Million | -17.36% |
| 2010-12-31 | $31.46 Million | +117.47% |
| 2009-12-31 | $14.47 Million | -53.27% |
| 2008-12-31 | $30.96 Million | -59.22% |
| 2007-12-31 | $75.91 Million | +19.97% |
| 2006-12-31 | $63.28 Million | +195.06% |
| 2005-12-31 | $21.45 Million | -61.43% |
| 2004-12-31 | $55.60 Million | +200.59% |
| 2003-12-31 | $18.50 Million | -14.10% |
| 2002-12-31 | $21.54 Million | -12.91% |
| 2001-12-31 | $24.73 Million | -13.17% |
| 2000-12-31 | $28.48 Million | -- |
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more